FDA flags safety concern after four deaths in schizophrenia drug trial

The U.S. Food and Drug Administration issued a warning after four participants died while receiving an experimental treatment for schizophrenia in a clinical study.

The agency described the observation as a potential safety signal, prompting a review of the trial data and possible modifications to the study protocol.

The column also noted an unrelated setback for Argenx and that Eli Lilly has filed lawsuits alleging that other companies are marketing copycat versions of its obesity medication, but details were not provided.